March 1, 2021 -- Pharmaron has purchased Allergan Biologics (ABL) for $118.7 million from AbbVie, expanding its cell and gene therapy (CGT) capabilities in the U.K.
The transaction will add ABL's Liverpool biomanufacturing facility to Pharmaron's business, allowing it to develop CGT products at a commercial scale, it said. The site will provide process research and development, current good manufacturing practice (cGMP) manufacturing, and advanced analytical capabilities for a range of biologics products. The company recently purchased Absorption Systems of Exton, PA, as part of its CGT service platform expansion.
The deal is expected to close in the second quarter of this year.